While injectable GLP-1 treatments remain the leading licensed choice for weight loss in the UK today, oral alternatives are quickly closing the gap
More about compounding concerns An open letter from Eli Lilly and Company regarding certain practices related to Mounjaro and Zepbound (June 2024) FDA warns about adverse events from compounded semaglutide (May 2023) Novo Nordisk escalates legal actions to safeguard patients from potentially harmful compounded semaglutide drugs (May 2024) The Center for Medicine in the Public Interest's September 2025 handout explains concerns about mass compounding
If you miss more than two weeks, most providers recommend stepping back one dose level and re-titrating over two to four weeks
We provide support for people with Type 2 Diabetes, Fatty Liver, Infertility, Erectile Dysfunction, Hypothyroidism, Hyperthyroidism, PCOS, Hirsutism, Adrenal Dysfunction, Menopause, Pituitary problems, Sexual Dysfunction, infertility and Osteoporosis